2025-08-06T11:50:58+00:00 2024-12-31 440160260 Forvis Mazars LLP 135 West 50th Street New York NY 10020 990 2024-01-01 362883000 American Liver Foundation AMER 2126681000 PO Box 229 West Orange NJ 07052 Lorraine Stiehl CEO 2126681000 2025-08-06 true Aaron Shapiro P01333816 2128674000 2025-08-06 2024 2025-03-06 01:10:19Z Lorraine Stiehl PO Box 229 West Orange NJ 07052 8797438 false X WWW.LIVERFOUNDATION.ORG X 1976 IL OUR MISSION IS TO FACILITATE, ADVOCATE, AND PROMOTE EDUCATION, SUPPORT SERVICES, AND RESEARCH FOR THE PREVENTION, TREATMENT, AND CURE OF LIVER DISEASE. 22 22 40 500 0 4896417 5097517 0 0 246747 709973 -135250 -146569 5007914 5660921 400000 943750 0 3344576 3845693 20000 131857 807731 1310034 1600612 5074610 6521912 -66696 -860991 9547099 8854388 1651882 1974787 7895217 6879601 X OUR MISSION IS TO FACILITATE, ADVOCATE, AND PROMOTE EDUCATION, SUPPORT SERVICES, AND RESEARCH FOR THE PREVENTION, TREATMENT, AND CURE OF LIVER DISEASE. true false 1250669 943750 SEE SCHEDULE O 1155394 SEE SCHEDULE O 1149300 SEE SCHEDULE O 1007617 COMMUNITY SERVICE: ALF conducts advocacy work on behalf of the patient community throughout the year, actively raising awareness of pertinent legislation affecting the liver community among the Federal government. * Launched our National Liver Awareness Month advocacy campaign on liver disease and obesity which resulted in 108 advocates sending a total of 343 messages and toolkits to Members of Congress. Additionally, 650 emails containing our toolkit and resources were sent to Congressional staff to reinforce awareness and understanding of the direct link between obesity and MASLD/MASH (formerly known as NAFLD/NASH). * Circulated an urgent letter to the Energy and Commerce and Senate Finance committees to request action on the inclusion of anti-obesity medications for seniors transitioning into Medicare. ALF's liver healthcare provider network was activated to send letters to representatives in target states, amplifying our impact through healthcare professionals' voices. ALF National Board Members and several advocacy ambassadors residing in key Congressional districts submitted letters to the editor and op-eds on the importance of the anti-obesity medications and the link to liver disease. * Conducted a Year-End Advocacy Survey and Briefing to determine what priorities matter most to them. In 2024, 513 people responded, up from 327 last year. As in years past, the #1 most important issue to our stakeholders is Early Diagnosis and Treatment of Liver Disease, followed by Research to Help Cure and Treat Liver Disease, and Cost of Medications. Prevention of Liver Disease and Improve Access to Liver Transplantation followed closely behind with the #1 barrier to care cited as High Out-Of Pocket Costs. * Determined through survey data that Fatty Liver Disease is the #1 disease ALF's base cares most about, (last year it was Autoimmune Liver Disease). Autoimmune liver disease was #2 with Liver Cancer in the third spot. 521646 PROFESSIONAL EDUCATION * ALF published Healthcare Connections, A Monthly Newsletter for Healthcare Professionals designed to share ALF's events, programs, and calls to action with patients/caregivers and colleagues. Nearly 3,000 medical professionals receive this publication monthly. * Liver medical experts assisted in the expansion of the healthcare professional database through introductions to their colleagues. Introductory meetings were held to create meaningful relationships leading to inclusion in ALF's database. Additionally, ALF connected with front-line provider non-liver expert healthcare professionals through partnerships with organizations such as the National Association of Nurse Practitioners in Women's Health, attendance at Pri-Med conferences, and the Project ECHO series. * The annual Liver Health Poster Competition was hosted. Early career liver healthcare professionals submitted patient friendly liver disease informational posters along with a brief video, resulting in expert educational content for patients. As a bonus, ALF bonds with a pipeline of future liver medical leaders. * Two Medical Student Liver Clubs partnered with ALF to educate fellow medical students and the community about the liver. These clubs serve as an opportunity to encourage medical students to choose liver as their specialty, ultimately creating a pipeline of future liver healthcare professional providers. 1529263 5084626 true true false false false false false false true true true false false false true false true false false false false false false true true false false true true true false false false false false false false false false false false false false false false false false false false false true 54 0 true 40 true false false false false false true true false false false false false false false X 22 22 false false false false false false false true true false false false true true true true true true true true false false CA CO CT DE DC FL GA AL HI ID IL IN IA KS KY LA ME AK MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA AZ RI SC SD TN TX UT VT VA AR WA WV WI WY X X DAVID TICKER 2126681000 PO BOX 229 WEST ORANGE NJ 07052 CARLO FRAPPOLLI SECRETARY 0.3 X X 0 0 0 EMMANUEL THOMAS MD PHD BOARD CHAIR 0.3 X X 0 0 0 GENE CAUTILLO TREASURER 0.3 X X 0 0 0 ALISHA MAVIS MD BOARD MEMBER 0.3 X 0 0 0 ALLAN DOERR BOARD MEMBER 0.3 X 0 0 0 ANNE DOYEN BOARD MEMBER 0.3 X 0 0 0 ARI COHEN MD FACS BOARD MEMBER 0.3 X 0 0 0 CONNIE DENEWETH BOARD MEMBER 0.3 X 0 0 0 DAVID COHEN MD PHD BOARD MEMBER 0.3 X 0 0 0 DAVID FRANK BOARD MEMBER 0.3 X 0 0 0 ELLEN RUCKER-SELLERS BOARD MEMBER 0.3 X 0 0 0 FRED KOSTECKI BOARD MEMBER 0.3 X 0 0 0 HAILEY PULEO BOARD MEMBER 0.3 X 0 0 0 JOHN BAYEUX III BOARD MEMBER 0.3 X 0 0 0 KEVIN LEE BOARD MEMBER 0.3 X 0 0 0 LIZ LEESMAN BOARD MEMBER 0.3 X 0 0 0 MATTHEW KOONZ BOARD MEMBER 0.3 X 0 0 0 MIKE BRAUNSTEIN BOARD MEMBER 0.3 X 0 0 0 PETER CULLEN BOARD MEMBER 0.3 X 0 0 0 PHIL SHIN BOARD MEMBER 0.3 X 0 0 0 RICHARD MILLER BOARD MEMBER 0.3 X 0 0 0 UDEME EKONG BOARD MEMBER 0.3 X 0 0 0 DAVID TICKER CFO 35.0 X 200815 0 23179 LORRAINE STIEHL CEO 35.0 X 231385 0 24525 JULIANN KIMBROUGH CHIEF MKTG, COMMS, PUBLIC AFF. 35.0 X 184465 0 7989 HEIDI DANIELS VP OF DEVELOPMENT 35.0 X 171637 0 29697 HELENE JORDAN NATL SR. DIRECTOR, Research Program MGMT 35.0 X 154599 0 16022 JACQUELINE DOMINGUEZ NATIONAL SENIOR DIRECTOR, ENGAGEMENT 35.0 X 136221 0 5829 KELLY SMITH VP OF EVENTS 35.0 X 155806 0 35093 SHERI SINGER NATL DIRECTOR, DEV./ENGAGEMENT 35.0 X 158578 0 708 1393506 0 143042 11 false true false Amplotech LLC PO Box 16422 San Juan PR 00908 Web Master & Marketing Support 187619 Bright Dot LLC 7424 Chapel Hill Rd Suite 107 Raleigh NC 27607 Major Gifts Cultivation 131857 2 1862 2176738 2918917 5097517 0 0 0 0 0 357056 357056 0 0 3050562 2697645 352917 0 352917 352917 227768 2176738 438872 -211104 -211104 OTHER 900099 64535 64535 0 0 0 0 64535 5660921 0 0 563404 375000 375000 568750 568750 672358 528772 69055 74531 2646527 2081443 271826 293258 63418 49849 6510 7059 200480 157585 20580 22315 262910 206658 26988 29264 106898 68079 5315 33504 54349 34613 2702 17034 131857 131857 16812 16812 378039 324731 25353 27955 74851 60431 14420 398309 193365 151583 53361 56857 45486 5470 5901 46253 36482 4620 5151 133663 116915 5454 11294 2527 2527 23319 18339 2396 2584 31551 24814 3241 3496 MISCELLANEOUS 166023 134896 9059 22068 HOTEL AND CATERING 111161 58418 64 52679 0 0 0 0 6521912 5084626 629555 807731 1943664 1458264 813057 853150 241647 450060 0 0 0 0 135054 173787 92575 41798 48989 50777 6223346 5757022 0 0 141342 111328 9547099 8854388 178903 287858 400000 850000 267500 62500 660578 658902 0 0 144901 115527 1651882 1974787 X 5136293 4473058 2758924 2406543 7895217 6879601 9547099 8854388 -860991 -154625 0 X false true true false X 5317288 6782864 5799860 4896417 5097517 27893946 0 0 5317288 6782864 5799860 4896417 5097517 27893946 1312614 26581332 45040 54832 92900 249077 357056 798905 0 184297 113635 49115 28655 64535 440237 29133088 0 0.91241 0.89305 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - OTHER, COLUMN A - 184297.0, COLUMN B - 113635.0, COLUMN C - 49115.0, COLUMN D - 28655.0, COLUMN E - 64535.0, COLUMN F - 440237.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true X 983052 149295 61500 1070847 943717 189335 150000 983052 1152635 -208918 943717 988115 164520 1152635 1222206 95449 329540 988115 0.0 0.6929 0.3071 false false 55677 33465 22212 36898 8333 28565 50777 Federal Income Taxes OPERATING LEASE LIABILITIES 115527 115527 5596382 -154625 106898 0 -47727 5644109 16812 0 16812 5660921 6611998 106898 0 106898 6505100 16812 0 16812 6521912 Schedule D, Part X, Line 2 ASC 740 Footnote MANAGEMENT HAS EVALUATED THEIR INCOME TAX POSITIONS UNDER THE GUIDANCE INCLUDED IN ASC 740. BASED ON THEIR REVIEW, MANAGEMENT HAS NOT IDENTIFIED ANY MATERIAL UNCERTAIN TAX POSITIONS TO BE RECORDED OR DISCLOSED IN THE FINANCIAL STATEMENTS. Schedule D, Part IV, Line 2b Explanation of escrow agreement FUNDS HELD ON BEHALF OF OTHERS - ALF ACTS AS AN ADMINISTRATOR FOR FUNDS COLLECTED ON BEHALF OF LIVER TRANSPLANT PATIENTS. ALF DISBURSES FUNDS TO COVER THE COST OF PROPERLY DOCUMENTED POST-SURGERY EXPENSES. Schedule D, Part V, Line 4 Intended uses of endowment funds THE INTENDED USE OF ENDOWMENT FUNDS HAS BEEN SPECIFIED BY THE DONOR. ALL FUNDS ON HAND ARE USED TO GENERATE INTEREST/DIVIDEND INCOME AND CAPITAL GAINS TO SUPPORT VARIOUS RESEARCH INITIATIVES. X X X X X true Brightdot LLC 3434 Edwards Mill Road Suite 112-14 3 Raleigh NC 27612 Major Gift Cultivation false 0 131857 -131857 0 131857 -131857 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY Boston Marathon 614845 614845 0 0 0 14983 32202 234 20587 Gala 377341 272341 105000 0 0 43127 138095 5068 3933 28 1412320 1289552 122768 0 0 89198 10816 7316 73313 2404506 2176738 227768 0 0 147308 181113 12618 97833 438872 -211104 true Cincinnati Children's Hospital Medical Center 333 Burnet Ave MLC 4900 Cincinnati OH 45229 310833936 501 (C) (3) 75000 0 LIVER DISEASE RESEARCH New York University LISOM Grants 550 First Avenue New York NY 10016 135562308 501 (C) (3) 75000 0 LIVER DISEASE RESEARCH The University of Toledo 2801 West Bancroft Street Toledo OH 43606 346401483 501 (C) (3) 75000 0 LIVER DISEASE RESEARCH University of North Carolina at Chapel Hill 104 Airport Drive Chapel Hill NC 27599 566001393 501 (C) (3) 75000 0 LIVER DISEASE RESEARCH Cedars Sinai Medical Center 8700 Beverly Blvd Los Angeles CA 90048 951644600 501 (C) (3) 75000 0 LIVER DISEASE RESEARCH 5 0 Post Doctoral Award 7 168750 0 PILOT GRANTS 8 400000 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds Award recipients are required to submit annual progress updates and fiscal officers are required to sign off that grant funds were used in accordance with grant terms. X X false false false false false false false false false LORRAINE STIEHL CEO 221385 0 10000 0 0 0 8981 0 15544 0 255910 0 0 0 DAVID TICKER CFO 200815 0 0 0 0 0 8137 0 15042 0 223994 0 0 0 JULIANN KIMBROUGH CHIEF MKTG, COMMS, PUBLIC AFF. 184465 0 0 0 0 0 6736 0 1253 0 192454 0 0 0 KELLY SMITH VP OF EVENTS 155806 0 0 0 0 0 6485 0 28608 0 190899 0 0 0 HEIDI DANIELS VP OF DEVELOPMENT 166637 0 5000 0 0 0 6597 0 23100 0 201334 0 0 0 SHERI SINGER NATL DIRECTOR, DEV./ENGAGEMENT 158578 0 0 0 0 0 0 0 708 0 159286 0 0 0 HELENE JORDAN NATL SR. DIRECTOR, Research Program MGMT 154599 0 0 0 0 0 0 0 16022 0 170621 0 0 0 Form 990, Part III, Line 4c PUBLIC AND PATIENT EDUCATION PUBLIC AND PATIENT EDUCATION: * Through ALF's signature public outreach campaign, Think Liver Think Life, ALF made great strides in raising awareness about fatty liver disease and screening at-risk individuals for fatty liver. The online Liver Health Quiz was completed by nearly 13,000 people interested in understanding their risk for fatty liver disease. Additionally, more than 1.425 million people learned more about their liver health. The quiz is currently available in Spanish as well as English. Over 60 Memorandums of Understanding have been signed by federally qualified health centers (FQHCs) and community clinics to conduct fatty liver testing. To date, 2,305 people participated in screenings to test for the prevalence of fatty liver and distributed 2,375 Rapid tests for Hepatitis C. Those who were screened were connected to care through calls and text messages. ALF TLTL staff became certified Project ECHO providers offering fatty liver education to the community clinicians, FQHC personnel and front-line healthcare providers on this respected platform. The ALF Project ECHO MASLD series launched in August 2024 and featured live presentations and case studies using the Project ECHO model. All sessions were recorded as enduring material for future on demand viewing. Another series is planned for 2025. ALF continues to evaluate non-invasive elastography testing equipment and engage new technology for Think Liver Think Life screening events. ALF established a volunteer fatty liver healthcare expert mentor group to provide expertise to support the clinicians who are identifying and treating newly diagnosed patients across the US. * ALF's Programs Team recruited 30 liver healthcare medical experts from 19 different institutions to share their knowledge resulting in enduring educational programming for patients/caregivers on the topics of liver cancer, Covid 19 update, 30-day menu for healthier living, hepatitis B & C, Hepatorenal Syndrome, clinical trials, the patient registry, and a Life with Pediatric Liver Disease Series. Priorities also included partnering with Hispanic Networks to educate their providers about the high prevalence of MASLD, diagnosis, and treatment therapies. As a result, ALF presented an inaugural educational program in Spanish accompanied by patient materials in Spanish. These materials were translated from English by volunteer bilingual liver healthcare experts. * Liver Health Today, ALF's monthly e-newsletter for patients and caregivers, was distributed monthly to 255,000 patients, supporters, and volunteers in 2023. New web content was updated and created on a variety of liver disease topics. The website was visited by more than 2.2 million unique visitors in 2023. Additionally, ALF reviews and updates existing content to reflect new discoveries. All ALF website content is vetted by a liver medical expert prior to launch. Form 990, Part III, Line 4b PATIENT SUPPORT PATIENT SUPPORT: These three areas of work have resulted in fulfillment of mission-related goals in 2024. Significant examples of ALF accomplishments are featured below. * Responded to 3,388 Helpline calls, live chats and emails from patients, caregivers and the public. * Hosted Facebook support groups for people with Primary Biliary Cholangitis, Liver Cancer, NASH (now known as MASH), Pediatric Liver Diseases and launched an Alcohol-Associated Liver Disease support group as well as an innovative Peer to Peer Patient Mentor Program (50 slots). In 2024, the cumulative total of participating Facebook support group members was 12,379. * Expanded our patient diversity through partnerships with organizations such as the Association of Black Gastroenterologists and Hepatologists, Blackdocotor.org, Migrant Clinicians Network, and Latinx Physicians of CA. * Served as the patient voice on Community Advisory Boards for 16 grant funded studies at the invitation of the medical grant lead investigators. * Held our first-ever Capitol Hill briefing on Obesity: The Leading Cause of Nonalcoholic Fatty Liver Disease and the Most Urgent Threat to Public Health Today in May 2024. This event addressed the growing concerns regarding obesity and its correlation with the increasing prevalence of liver disease nationwide. Form 990, Part III, Line 4a RESEARCH RESEARCH American Liver Foundation (ALF) has a history of commitment to research funding dating back to 1979. In 2023 with the approval of ALF's National Board of Directors, ALF established a dedicated Research Department led by an experienced PhD. Growth has been exponential in terms of meaningful pilot research grant opportunities for experienced researchers and grant awards to support the pipeline of early career researchers. ALF's 2024 priorities included a focus on childhood and rare disease challenges. Grant selection integrity was gained through the establishment of a formal Grants Review Committee comprised of respected liver experts. The patient voice was integrated into the process through the newly established Patient Research Advisory Group. Key accomplishments included: * Disease-specific Pilot Grant Awards in Autoimmune Hepatitis (AIH), Biliary Atresia (BA), Primary Biliary Cholangitis (PBC), and Primary Sclerosing Cholangitis (PSC): These grants provide $50,000 funding for research projects in new areas of investigation, innovative ideas, or "high-risk, high-reward" projects that have the potential to generate breakthrough findings and significantly advance the field. Applications were submitted for all four diseases: (6 for AIH, 3 for PBC, 18 for PSC, and 6 for BA) resulting in funding 8 pilot grants in October 2024, using restricted funds from previous years to support quality applications in AIH (1), PSC (3), and BA (4) (no application was deemed meritorious for PBC). * Early Career Awards: In August 2024 the Research Department issued RFPs for Liver Scholar (LS) and Postdoctoral Fellowship (PD) Awards and received a record number of applications. A record 9 LS and 21 PD applications were identified as "high impact 2 Liver Scholar Awards were granted at $225,000 (over a 3-year period) and 6 Postdoctoral Fellowship Awards of $25,000. * American Liver Foundation Patient Registry: Launched in July 2024, this registry uniquely includes ALL liver diseases versus liver disease registries focused on one liver disease. Nearly 700 participants self-enrolled from the initial launch through the end of 2024. * Distinguished Scientific Achievement Award (DSAA): Annual recognition ceremony to promote and acknowledge the outstanding work of researchers. ALF's 2024 DSAA award recipient was Dr. Jacquelyn Maher (UCSF), selected by an independent panel of liver experts. The ALF Research Program was promoted at the annual AASLD (American Association for the Study of Liver Diseases) Liver Meeting through interactions with a variety of stakeholders, including academic researchers, industry partners, patients, and other non-profit organizations. Form 990, Part III, Line 2 New program services American Liver Foundation Patient Registry: Launched in July 2024, this registry uniquely includes ALL liver diseases versus liver disease registries focused on one liver disease. Nearly 700 participants self-enrolled from the initial launch through the end of 2024. Form 990, Part III, Line 4d Description of other program services (Expenses $ 1,007,617 including grants of $) COMMUNITY SERVICE: ALF conducts advocacy work on behalf of the patient community throughout the year, actively raising awareness of pertinent legislation affecting the liver community among the Federal government. * Launched our National Liver Awareness Month advocacy campaign on liver disease and obesity which resulted in 108 advocates sending a total of 343 messages and toolkits to Members of Congress. Additionally, 650 emails containing our toolkit and resources were sent to Congressional staff to reinforce awareness and understanding of the direct link between obesity and MASLD/MASH (formerly known as NAFLD/NASH). * Circulated an urgent letter to the Energy and Commerce and Senate Finance committees to request action on the inclusion of anti-obesity medications for seniors transitioning into Medicare. ALF's liver healthcare provider network was activated to send letters to representatives in target states, amplifying our impact through healthcare professionals' voices. ALF National Board Members and several advocacy ambassadors residing in key Congressional districts submitted letters to the editor and op-eds on the importance of the anti-obesity medications and the link to liver disease. * Conducted a Year-End Advocacy Survey and Briefing to determine what priorities matter most to them. In 2024, 513 people responded, up from 327 last year. As in years past, the #1 most important issue to our stakeholders is Early Diagnosis and Treatment of Liver Disease, followed by Research to Help Cure and Treat Liver Disease, and Cost of Medications. Prevention of Liver Disease and Improve Access to Liver Transplantation followed closely behind with the #1 barrier to care cited as High Out-Of Pocket Costs. * Determined through survey data that Fatty Liver Disease is the #1 disease ALF's base cares most about, (last year it was Autoimmune Liver Disease). Autoimmune liver disease was #2 with Liver Cancer in the third spot. Form 990, Part III, Line 4d Description of other program services (Expenses $ 521,646 including grants of $) PROFESSIONAL EDUCATION * ALF published Healthcare Connections, A Monthly Newsletter for Healthcare Professionals designed to share ALF's events, programs, and calls to action with patients/caregivers and colleagues. Nearly 3,000 medical professionals receive this publication monthly. * Liver medical experts assisted in the expansion of the healthcare professional database through introductions to their colleagues. Introductory meetings were held to create meaningful relationships leading to inclusion in ALF's database. Additionally, ALF connected with front-line provider non-liver expert healthcare professionals through partnerships with organizations such as the National Association of Nurse Practitioners in Women's Health, attendance at Pri-Med conferences, and the Project ECHO series. * The annual Liver Health Poster Competition was hosted. Early career liver healthcare professionals submitted patient friendly liver disease informational posters along with a brief video, resulting in expert educational content for patients. As a bonus, ALF bonds with a pipeline of future liver medical leaders. * Two Medical Student Liver Clubs partnered with ALF to educate fellow medical students and the community about the liver. These clubs serve as an opportunity to encourage medical students to choose liver as their specialty, ultimately creating a pipeline of future liver healthcare professional providers. Form 990, Part VI, Line 11b Review of form 990 by governing body A DRAFT OF THE FORM 990 IS SENT TO THE FINANCE COMMITTEE FOR REVIEW AND COMMENTS IN THE MONTHLY MEETING PRIOR TO FILING. IN ADDITION, A DRAFT OF THE FORM 990 IS ALSO SENT TO EACH BOARD MEMBER FOR DISCUSSION. AFTER QUESTIONS AND COMMENTS ARE ADDRESSED AND THE FORM 990 IS APPROVED, IT IS READY FOR FILING. Form 990, Part VI, Line 12c Conflict of interest policy ANNUALLY, OUR CONFLICT OF INTEREST FORM IS COMPLETED BY OFFICERS AND DIRECTORS. THE FORM MUST INDICATE ANY POSSIBLE CONFLICTS OF INTEREST AND IS SIGNED BY ALL OFFICERS AND DIRECTORS. WHEN ANY SUCH CONFLICT OF INTEREST IS RELEVANT TO A MATTER REQUIRING ACTION BY THE BOARD, THE INTERESTED PERSON SHALL CALL IT TO THE ATTENTION OF THE BOARD AND SUCH PERSON SHALL NOT VOTE ON THE MATTER. MOREOVER, THE PERSON HAVING A CONFLICT SHALL RETIRE FROM THE ROOM IN WHICH THE BOARD IS MEETING AND SHALL NOT PARTICIPATE IN THE FINAL DELIBERATION OR DECISION REGARDING THE MATTER UNDER CONSIDERATION. HOWEVER, THAT PERSON SHALL PROVIDE THE BOARD WITH ANY AND ALL RELEVANT INFORMATION. THE MINUTES OF THE MEETING OF THE BOARD, SHALL REFLECT THAT THE CONFLICT OF INTEREST WAS DISCLOSED AND THAT THE INTERESTED PERSON WAS NOT PRESENT DURING THE FINAL DISCUSSION OR VOTE AND DID NOT VOTE. WHEN THERE IS A DOUBT AS TO WHETHER A CONFLICT OF INTEREST EXISTS, THE MATTER SHALL BE RESOLVED BY A VOTE OF THE BOARD. Form 990, Part VI, Line 15a Process to establish compensation of top management official CEO COMPENSATION IS DETERMINED BY THE NATIONAL BOARD OF DIRECTOR'S EXECUTIVE COMMITTEE AND APPROVED BY THE BOARD MEMBERS. IN DETERMINING SALARY LEVELS, THE EXECUTIVE COMMITTEE REVIEWS AN ANNUAL SALARY SURVEY OF NATIONAL VOLUNTARY HEALTH ORGANIZATIONS PREPARED FOR THE NATIONAL HEALTH COUNCIL AND REVIEWS PRIOR YEAR PERFORMANCE. CURRENT MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION ARE ALSO CONSIDERED IN SETTING COMPENSATION. THIS REVIEW WAS LAST CONDUCTED IN 2024. Form 990, Part VI, Line 15b Process to establish compensation of other employees THE SALARY OF OFFICERS AND KEY EMPLOYEES ARE DETERMINED BY THE CEO AND CFO BASED ON PERFORMANCE, MARKET CONDITIONS AND THE FINANCIAL CONDITION OF THE AMERICAN LIVER FOUNDATION. Form 990, Part VI, Line 19 Required documents available to the public THE ANNUAL AUDIT REPORT AND FORM 990 ARE AVAILABLE VIA WWW.LIVERFOUNDATION.ORG AND FORM 1023 AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST.